Literature DB >> 15899860

Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27.

Fiona A Mack1, Jagruti H Patel, Mangatt P Biju, Volker H Haase, M Celeste Simon.   

Abstract

Inactivating mutations within the von Hippel-Lindau (VHL) tumor suppressor gene predispose patients to develop a variety of highly vascularized tumors. pVHL targets alpha subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF), a critical regulator of energy metabolism, angiogenesis, hematopoiesis, and oxygen (O(2)) delivery, for ubiquitin-mediated degradation in an O(2)-dependent manner. To investigate the role of Vhl in cellular proliferation and tumorigenesis, we utilized mouse embryonic fibroblasts (MEFs), a common tool for analyzing cell cycle regulation, and generated Vhl(-)(/)(-) MEF-derived fibrosarcomas. Surprisingly, growth of both Vhl(-)(/)(-) MEFs and fibrosarcomas was impaired, although tumor vascularity was increased. Decreased proliferation of Vhl(-)(/)(-) MEFs was correlated with an overexpression of cyclin kinase inhibitors (CKIs) p21 and p27. The transcription of p21 and p27 is inhibited by c-Myc; therefore, the induction of CKIs was attributed to the ability of HIF to antagonize c-Myc activity. Indeed, p21 mRNA levels were elevated under normoxia in Vhl(-)(/)(-) MEFs, while c-Myc transcriptional activity was markedly reduced. Gene silencing of HIF-1alpha by small interfering RNA reduced p21 and p27 protein and mRNA levels in Vhl(-)(/)(-) MEFs. The induction of p21 and p27, mediated by constitutive activation of the HIF pathway, provides a mechanism for the decreased proliferation rates of Vhl(-)(/)(-) MEFs and fibrosarcomas. These results demonstrate that a loss of pVHL can induce growth arrest in certain cells types, which suggests that additional genetic mutations are necessary for VHL-associated tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899860      PMCID: PMC1140627          DOI: 10.1128/MCB.25.11.4565-4578.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  42 in total

1.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

2.  Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha.

Authors:  Sang-Ki Park; Agnes M Dadak; Volker H Haase; Lucrezia Fontana; Amato J Giaccia; Randall S Johnson
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

3.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

Authors:  Stefano J Mandriota; Kevin J Turner; David R Davies; Paul G Murray; Neil V Morgan; Heidi M Sowter; Charles C Wykoff; Eamonn R Maher; Adrian L Harris; Peter J Ratcliffe; Patrick H Maxwell
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

4.  Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth.

Authors:  Fiona A Mack; W Kimryn Rathmell; Andrew M Arsham; James Gnarra; Brian Keith; M Celeste Simon
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

5.  Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.

Authors:  Masaya Baba; Syuiohi Hirai; Hisafumi Yamada-Okabe; Kenji Hamada; Hisahiro Tabuchi; Kazuki Kobayashi; Keiichi Kondo; Minoru Yoshida; Akio Yamashita; Takeshi Kishida; Noboru Nakaigawa; Youji Nagashima; Yoshinobu Kubota; Masahiro Yao; Shigeo Ohno
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

6.  Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

Authors:  Alexander Hergovich; Joanna Lisztwan; Robert Barry; Pia Ballschmieter; Wilhelm Krek
Journal:  Nat Cell Biol       Date:  2003-01       Impact factor: 28.824

7.  The hypoxic response of tumors is dependent on their microenvironment.

Authors:  Barbara Blouw; Hanqiu Song; Tarik Tihan; Jenel Bosze; Napoleone Ferrara; Hans Peter Gerber; Randall S Johnson; Gabriele Bergers
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

8.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Authors:  Michael Zimmer; Darrell Doucette; Naila Siddiqui; Othon Iliopoulos
Journal:  Mol Cancer Res       Date:  2004-02       Impact factor: 5.852

9.  Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.

Authors:  Keiichi Kondo; William Y Kim; Mirna Lechpammer; William G Kaelin
Journal:  PLoS Biol       Date:  2003-12-22       Impact factor: 8.029

10.  Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene.

Authors:  C C Wykoff; C Sotiriou; M E Cockman; P J Ratcliffe; P Maxwell; E Liu; A L Harris
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

View more
  37 in total

1.  Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis.

Authors:  Armin M Gamper; Xinxian Qiao; Jennifer Kim; Liyong Zhang; Michelle C DeSimone; W Kimryn Rathmell; Yong Wan
Journal:  Mol Cell       Date:  2012-01-27       Impact factor: 17.970

2.  The tumor suppressor von Hippel-Lindau gene product and metastasis: new thoughts on an old molecule.

Authors:  Debabrata Mukhopadhyay
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

3.  von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.

Authors:  Ying Yi; Olga Mikhaylova; Aygun Mamedova; Prabhat Bastola; Jacek Biesiada; Enas Alshaikh; Linda Levin; Rachel M Sheridan; Jarek Meller; Maria F Czyzyk-Krzeska
Journal:  Clin Cancer Res       Date:  2010-10-26       Impact factor: 12.531

4.  Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress.

Authors:  Scott M Welford; Mary Jo Dorie; Xiaofeng Li; Volker H Haase; Amato J Giaccia
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

5.  Hypoxia, HIFs and bone development.

Authors:  Elisa Araldi; Ernestina Schipani
Journal:  Bone       Date:  2010-05-02       Impact factor: 4.398

6.  Suppression of von Hippel-Lindau Protein in Fibroblasts Protects against Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Qiyuan Zhou; Tianji Chen; Wei Zhang; Melike Bozkanat; Yongchao Li; Lei Xiao; Richard B van Breemen; John W Christman; Jacob I Sznajder; Guofei Zhou
Journal:  Am J Respir Cell Mol Biol       Date:  2016-05       Impact factor: 6.914

7.  Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma.

Authors:  Tatsuaki Tagami; Takuya Suzuki; Kiyomi Hirose; Jose Mario Barichello; Naoshi Yamazaki; Tomohiro Asai; Naoto Oku; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Drug Deliv Transl Res       Date:  2011-08       Impact factor: 4.617

Review 8.  The multiple layers of ubiquitin-dependent cell cycle control.

Authors:  Katherine Wickliffe; Adam Williamson; Lingyan Jin; Michael Rape
Journal:  Chem Rev       Date:  2009-04       Impact factor: 60.622

Review 9.  Regulation of cell proliferation by hypoxia-inducible factors.

Authors:  Maimon E Hubbi; Gregg L Semenza
Journal:  Am J Physiol Cell Physiol       Date:  2015-10-21       Impact factor: 4.249

10.  The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress.

Authors:  Olga Mikhaylova; Monika L Ignacak; Teresa J Barankiewicz; Svetlana V Harbaugh; Ying Yi; Patrick H Maxwell; Martin Schneider; Katie Van Geyte; Peter Carmeliet; Monica P Revelo; Michael Wyder; Kenneth D Greis; Jarek Meller; Maria F Czyzyk-Krzeska
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.